Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

Novozymes A/S ADR (NVZMY-PK) is in the process of merging with another Danish company to enter the biologics industry, a move that has received mixed reviews. While some experts believe the deal will offer growth opportunities and lead to an increase in share prices, others initially had concerns about the price being paid. However, the consensus is that the company's dividend growth averages 10% and the overall outlook is positive, with experts adding shares to their portfolios in anticipation of continued growth.

Consensus
Positive
Valuation
Fair Value
BUY

Are merging with another Danish company which will remake the company because it gets them into the biologics industry. The street didn't like the price they were paying at first, but the deal offers growth. Shares have been growing and will continue to do. Their dividend growth averages 10%. He's adding shares.

0
HOLD
Can be cyclical. Baking, laundry pods, bacteria eating landfill sites. Likes the company. No debt, so lot of the risk disappears. Last quarter weak, price came down, so it was time to buy more. In the right sector, doing the right things, and it's always nice to help the planet. Long-term hold.
0
BUY ON WEAKNESS

This is an industrial enzymes company, spun out of Novo Nordisk. It has been a solid performer with a good balance sheet. The problem is that there are rarely good buying opportunities. It trades at a high earnings multiple and rarely misses earnings estimates, for example. This would be a good company to buy in a recession.

0
Showing 1 to 3 of 3 entries
  • «
  • 1
  • »

Novozymes A/S ADR (NVZMY-PK) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Novozymes A/S ADR is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novozymes A/S ADR (NVZMY-PK) Frequently Asked Questions

What is Novozymes A/S ADR stock symbol?

Novozymes A/S ADR is a OTC stock, trading under the symbol NVZMY-PK on the (). It is usually referred to as or NVZMY-PK

Is Novozymes A/S ADR a buy or a sell?

In the last year, 1 stock analyst published opinions about NVZMY-PK. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novozymes A/S ADR .

Is Novozymes A/S ADR a good investment or a top pick?

Novozymes A/S ADR was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Novozymes A/S ADR .

Why is Novozymes A/S ADR stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novozymes A/S ADR worth watching?

In the last year, there was no coverage of Novozymes A/S ADR published on Stockchase.

What is Novozymes A/S ADR stock price?

On , Novozymes A/S ADR (NVZMY-PK) stock closed at a price of $.